<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02973646</url>
  </required_header>
  <id_info>
    <org_study_id>PL2</org_study_id>
    <nct_id>NCT02973646</nct_id>
  </id_info>
  <brief_title>Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection</brief_title>
  <official_title>Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to observe the anti-HBV therapeutic effects of peginterferon alfa-2b in chronic&#xD;
      hepatitis b patients with e antigen positive based on the detection of interferon gene&#xD;
      mutation (IFNA2 p.Ala120Thr) and interferon receptor (IFNAR2) detection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with e antigen positive chronic hepatitis b were enrolled in the study. Age, sex,&#xD;
      symptoms (e.g., fever, fatigue, poor appetite, jaundice) were recorded in the study. We also&#xD;
      observed the laboratory test results including the levels of white blood cells (WBC), red&#xD;
      blood cells (RBC), hemoglobin (HGB), platelet (PLT), alanine transaminase (ALT), aspartate&#xD;
      transaminase (AST), hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg),&#xD;
      hepatitis B e antibody (HBeAb), and hepatitis B virus (HBV) DNA; detection of gene mutation&#xD;
      (IFNA2 p.Ala120Thr), levels of interferon receptor (IFNAR2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>good virologic response</measure>
    <time_frame>24th week</time_frame>
    <description>level of HBsAg is less than or equal to 1500 IU/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>common virologic response</measure>
    <time_frame>24th week</time_frame>
    <description>level of HBsAg is more than 1500 IU/ml, also less than or equal to 20000 IU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bad virologic response</measure>
    <time_frame>24th week</time_frame>
    <description>level of HBsAg is more than 20000 IU/ml, level of HBV DNA is equal to or more than 4.0 log10 IU/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Nucleos(t)ide analogues treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with interferon receptor level down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 24th week, then nucleos(t)ide analogues (entecavir tablet 0.5mg/d or tenofovir tablet 300mg/d) from 25th to 36th week, then peginterferon alfa-2b injection 80ug/d again from 36th to 48th week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with interferon receptor level not down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 48th week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir or Tenofovir</intervention_name>
    <description>Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.</description>
    <arm_group_label>Nucleos(t)ide analogues treatment</arm_group_label>
    <other_name>Baraclude</other_name>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alfa-2B</intervention_name>
    <arm_group_label>Nucleos(t)ide analogues treatment</arm_group_label>
    <arm_group_label>Peginterferon treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic hepatitis b Patients who should receive anti-HBV therapy according to&#xD;
             guideline and are willing to receive interferon therapy;&#xD;
&#xD;
          2. Hepatitis B e antigen positive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients received anti-HBV therapy in the past 6 months;&#xD;
&#xD;
          2. Patients with liver cirrhosis or hepatocellular carcinoma or other malignancies;&#xD;
&#xD;
          3. Patients with other factors causing active liver diseases;&#xD;
&#xD;
          4. Pregnancy or lactation women;&#xD;
&#xD;
          5. Patients with HIV infection or congenital immune deficiency diseases;&#xD;
&#xD;
          6. Patients with severe diabetes, autoimmune diseases, other important organ dysfunctions&#xD;
             and other serious complications.&#xD;
&#xD;
          7. Patients with other reasons not suitable to receive interferon therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Peng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenxiong Xu, Master</last_name>
    <phone>+8613760783281</phone>
    <email>xwx1983@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Peng, Doctor</last_name>
    <phone>+8613533978874</phone>
    <email>pzp33@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Peng, Doctor</last_name>
      <phone>+8613533978874</phone>
      <email>pzp33@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2016</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liang Peng</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis b</keyword>
  <keyword>peginterferon alfa-2b</keyword>
  <keyword>interferon gene mutation</keyword>
  <keyword>interferon receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

